BR112022005660A2 - Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos. - Google Patents

Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.

Info

Publication number
BR112022005660A2
BR112022005660A2 BR112022005660A BR112022005660A BR112022005660A2 BR 112022005660 A2 BR112022005660 A2 BR 112022005660A2 BR 112022005660 A BR112022005660 A BR 112022005660A BR 112022005660 A BR112022005660 A BR 112022005660A BR 112022005660 A2 BR112022005660 A2 BR 112022005660A2
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical use
fxia
inhibitors
fxia inhibitors
Prior art date
Application number
BR112022005660A
Other languages
English (en)
Inventor
Junjun Wu
Yinsuo Lu
Ying Xiao
Zexin Hong
Jianli Wu
Wei Xing
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of BR112022005660A2 publication Critical patent/BR112022005660A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE FXIA E MÉTODO DE PREPARAÇÃO DOS MESMOS E USO FARMACÊUTICO DOS MESMOS. É fornecida na presente invenção uma série de inibidores de Fator XIa seletivo (FXIa), relacionados ao campo da técnica de fármacos químicos. A presente invenção também se refere a composições farmacêuticas que contêm as ditas composições e a um uso das ditas composições em fármacos para o tratamento de doenças, tais como tromboembolismo.
BR112022005660A 2019-09-27 2020-09-24 Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos. BR112022005660A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910923960 2019-09-27
CN201911318870 2019-12-19
CN202010902000 2020-09-01
PCT/CN2020/117257 WO2021057818A1 (zh) 2019-09-27 2020-09-24 FXIa抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
BR112022005660A2 true BR112022005660A2 (pt) 2022-07-12

Family

ID=75165578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005660A BR112022005660A2 (pt) 2019-09-27 2020-09-24 Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.

Country Status (14)

Country Link
US (1) US20230027295A1 (pt)
EP (1) EP4036087A4 (pt)
JP (1) JP7450024B2 (pt)
KR (1) KR20220084301A (pt)
CN (2) CN116120240A (pt)
AU (1) AU2020355830B2 (pt)
BR (1) BR112022005660A2 (pt)
CA (1) CA3152667A1 (pt)
CO (1) CO2022005082A2 (pt)
EC (1) ECSP22032851A (pt)
MX (1) MX2022003649A (pt)
TW (1) TWI756848B (pt)
WO (1) WO2021057818A1 (pt)
ZA (1) ZA202202932B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083706A1 (zh) * 2020-10-23 2022-04-28 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途
CN115427043B (zh) * 2020-10-23 2023-04-07 深圳信立泰药业股份有限公司 FXIa抑制剂化合物或其盐的医药用途
CN117480164A (zh) * 2020-12-11 2024-01-30 上海领泰生物医药科技有限公司 凝血因子XIa抑制剂及其制备方法和应用
TW202246219A (zh) * 2021-03-18 2022-12-01 大陸商深圳信立泰藥業股份有限公司 ＦＸＩａ抑制劑化合物雜質、其製備方法及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
ATE230414T1 (de) 1998-02-12 2003-01-15 Molecumetics Ltd Mimetika von beta-faltblatt und verfahren zur verwendung davon
AU2003243657A1 (en) 2002-06-26 2004-01-19 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 ＸＩａ 억제제로서 피리디논 및 피리미디논 유도체
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
ES2754599T3 (es) * 2015-08-05 2020-04-20 Bristol Myers Squibb Co Nuevos inhibidores de FXIa derivados de glicina sustituidos
HUE057289T2 (hu) * 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
CN107793396B (zh) * 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
WO2018081377A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
CN111094241B (zh) * 2018-02-27 2022-06-21 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及其制备方法

Also Published As

Publication number Publication date
EP4036087A4 (en) 2023-09-20
ECSP22032851A (es) 2022-08-31
CN114206854A (zh) 2022-03-18
JP2022550367A (ja) 2022-12-01
TW202112374A (zh) 2021-04-01
WO2021057818A1 (zh) 2021-04-01
JP7450024B2 (ja) 2024-03-14
EP4036087A1 (en) 2022-08-03
TWI756848B (zh) 2022-03-01
MX2022003649A (es) 2022-06-08
CA3152667A1 (en) 2021-04-01
AU2020355830A1 (en) 2022-03-31
AU2020355830A9 (en) 2022-07-21
CO2022005082A2 (es) 2022-05-20
US20230027295A1 (en) 2023-01-26
CN116120240A (zh) 2023-05-16
CN114206854B (zh) 2023-02-24
AU2020355830B2 (en) 2023-04-13
ZA202202932B (en) 2022-11-30
KR20220084301A (ko) 2022-06-21

Similar Documents

Publication Publication Date Title
BR112022005660A2 (pt) Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW201613885A (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
NO20085100L (no) Nye forbindelser
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
CY1122689T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
MA50450B1 (fr) Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent